Literature DB >> 10798827

Are stimulants overprescribed for youths with ADHD?

D J Safer1.   

Abstract

Critics of stimulant treatment for youths with attention deficit hyperactivity disorder (ADHD) have increased their rhetoric of late, contending that the leading medication for it, Ritalin, is vastly overprescribed. Additionally, they claim that Ritalin (methylphenidate) is inherently dangerous and that the entire system of the diagnosis and treatment of ADHD is seriously flawed. The critics view the underlying reason for the "epidemic" as societal, due to our modern pace of living, our competitive society, and our consumer emphasis. Rejoinders to and clarifications of the more tangible points of the critics are presented, followed by a discussion of some more practical and legitimate concerns for researchers in this area. These concerns include changes within the ADHD category, the clinical need for multiple sources of diagnostic data, infrequent teacher-physician communication, problematic ADHD/conduct disorder comorbidity in adolescence, and the limited amount of community-based research.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10798827     DOI: 10.1023/a:1009031211900

Source DB:  PubMed          Journal:  Ann Clin Psychiatry        ISSN: 1040-1237            Impact factor:   1.567


  11 in total

1.  Prevalence rates of youths diagnosed with and medicated for ADHD in a nationwide survey in Taiwan from 2000 to 2011.

Authors:  L-J Wang; S-Y Lee; S-S Yuan; C-J Yang; K-C Yang; T-S Huang; W-J Chou; M-C Chou; M-J Lee; T-L Lee; Y-C Shyu
Journal:  Epidemiol Psychiatr Sci       Date:  2016-07-20       Impact factor: 6.892

2.  No increases in biomarkers of genetic damage or pathological changes in heart and brain tissues in male rats administered methylphenidate hydrochloride (Ritalin) for 28 days.

Authors:  Kristine L Witt; David E Malarkey; Cheryl A Hobbs; Jeffrey P Davis; Grace E Kissling; William Caspary; Gregory Travlos; Leslie Recio
Journal:  Environ Mol Mutagen       Date:  2010-01       Impact factor: 3.216

3.  Is attention deficit hyperactivity disorder increasing among girls in the US? Trends in diagnosis and the prescribing of stimulants.

Authors:  Linda M Robison; Tracy L Skaer; David A Sclar; Richard S Galin
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

4.  Sequential evaluation of behavioral treatments and methylphenidate dosage for children with attention deficit hyperactivity disorder.

Authors:  Veronica Gulley; John Northup; Steve Hupp; Sandi Spera; Jim LeVelle; Andrea Ridgway
Journal:  J Appl Behav Anal       Date:  2003

5.  Assessing methylphenidate preference in ADHD patients using a choice procedure.

Authors:  Emily MacDonald Fredericks; Scott H Kollins
Journal:  Psychopharmacology (Berl)       Date:  2004-10       Impact factor: 4.530

6.  Methylphenidate and amphetamine do not induce cytogenetic damage in lymphocytes of children with ADHD.

Authors:  Kristine L Witt; Michael D Shelby; Nilda Itchon-Ramos; Melissa Faircloth; Grace E Kissling; Allan K Chrisman; Hima Ravi; Hemalatha Murli; Donald R Mattison; Scott H Kollins
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2008-12       Impact factor: 8.829

7.  Prevalence of methylphenidate use among Canadian children following parental divorce.

Authors:  Lisa A Strohschein
Journal:  CMAJ       Date:  2007-06-05       Impact factor: 8.262

8.  Illicit methylphenidate use among Iranian medical students: prevalence and knowledge.

Authors:  Afshin Habibzadeh; Mahasti Alizadeh; Ayoub Malek; Leili Maghbooli; Mohammadali M Shoja; Kamyar Ghabili
Journal:  Drug Des Devel Ther       Date:  2011-02-03       Impact factor: 4.162

Review 9.  Misuse of "study drugs:" prevalence, consequences, and implications for policy.

Authors:  Steve Sussman; Mary Ann Pentz; Donna Spruijt-Metz; Toby Miller
Journal:  Subst Abuse Treat Prev Policy       Date:  2006-06-09

10.  Co-morbidity and patterns of care in stimulant-treated children with ADHD in the Netherlands.

Authors:  Adrianne Faber; Luuk J Kalverdijk; Lolkje T W de Jong-van den Berg; Jacqueline G Hugtenburg; Ruud B Minderaa; Hilde Tobi
Journal:  Eur Child Adolesc Psychiatry       Date:  2009-11-06       Impact factor: 4.785

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.